Your browser doesn't support javascript.
loading
Patient with inoperable pheochromocytoma.
Brancíková, D; Mechl, Z; Adam, Z; Jandáková, E; Pavlovský, Z; Válek, V; Andrasina, Z.
Affiliation
  • Brancíková D; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Internal Hematological and Oncological Clinic, University Hospital Brno, Brno, Czech Republic;
  • Mechl Z; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Internal Hematological and Oncological Clinic, University Hospital Brno, Brno, Czech Republic;
  • Adam Z; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Internal Hematological and Oncological Clinic, University Hospital Brno, Brno, Czech Republic;
  • Jandáková E; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Institute of Pathology, University Hospital Brno, Brno, Czech Republic;
  • Pavlovský Z; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Department of Radiology, University Hospital Brno, Brno, Czech Republic.
  • Válek V; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Department of Radiology, University Hospital Brno, Brno, Czech Republic.
  • Andrasina Z; Medical Faculty, Masaryk University, Brno, Czech Republic; ; Department of Radiology, University Hospital Brno, Brno, Czech Republic.
Curr Oncol ; 22(3): e216-9, 2015 Jun.
Article in En | MEDLINE | ID: mdl-26089731
ABSTRACT
Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Oncol Year: 2015 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Oncol Year: 2015 Type: Article